U.S. Pharma Stock News

In recent weeks, Biohaven announced first-in-human dosing for BHV-8100, an oral brain-penetrant PKM2 modulator, alongside early clinical data showing deep, rapid antibody reductions with its degrader candidates BHV-1300 for Graves’ disease and BHV-1400 for IgA nephropathy. These updates highlight Biohaven’s attempt to build a differentiated portfolio that links brain energy metabolism with precision immunology across neurology and autoimmune disorders. Next, we’ll examine how Biohaven’s push...

NIKE (NKE) is back in focus after RBC Capital Markets cut its rating to Sector Perform from Outperform, citing slower turnaround progress, operational friction between channels, and tougher competition in premium activewear. See our latest analysis for NIKE. The downgrade comes after a difficult period for shareholders, with the share price down about 19% over three months and the 1-year total shareholder return falling roughly 28%, even though the past month’s share price return has turned...

Septerna, Inc. recently announced that detailed preclinical characterization data for SEP-479, its potent and selective oral PTH1R agonist for hypoparathyroidism, has been accepted for an oral presentation at the 2026 Endocrine Society’s Annual Meeting, with the program currently in an ongoing Phase 1 trial. This conference spotlight offers scientific validation and industry visibility for SEP-479’s potential to functionally replace parathyroid hormone with once-daily oral therapy, a...

Casey's General Stores (CASY) is back in focus after reporting fourth quarter and full year results that topped expectations, paired with a 14% dividend increase and a larger share repurchase authorization. See our latest analysis for Casey's General Stores. The latest earnings, dividend increase and expanded buyback have coincided with a sharp reset in expectations, with a 1 day share price return of 20.29% and year to date share price return of 64.60%. Over 5 years, a total shareholder...

Cheetah Mobile (NYSE:CMCM) has put fresh numbers on the table for Q1 2026, reporting revenue of ¥259.0 million and a basic EPS loss of ¥0.56, while trailing 12 month revenue stands at ¥1.15 billion with a basic EPS loss of ¥8.21. Over recent quarters, the company has seen revenue fluctuate between about ¥237.1 million and ¥308.9 million, with basic EPS losses ranging from ¥0.35 to ¥12.38, which keeps the spotlight firmly on how efficiently each yuan of sales is translating into earnings. With...

Dividend and sentiment driven move in InvenTrust Properties Recent coverage of InvenTrust Properties (IVT) has focused on its consistent dividend growth, its current $0.25 per share payout, and its constructive earnings outlook, which appear linked to the stock’s recent positive trading momentum. See our latest analysis for InvenTrust Properties. InvenTrust Properties' recent momentum stands out, with a 7 day share price return of 6.72% and a year to date share price return of 24.68%. The 5...

Sportradar Group AG recently announced a multi-year global agreement naming it the official data and solutions provider to prediction market operator Kalshi, supplying real-time sports data, odds, engagement tools, marketing services, and integrity monitoring across major properties including MLB, NHL, MLS, and UFC. This deal extends Sportradar’s core data infrastructure into the regulated prediction markets segment, highlighting how its integrity and compliance tools are becoming essential...

In recent days, Option Care Health has drawn attention as Goldman Sachs initiated coverage with a Neutral rating while Bank of America moved to a more cautious stance, even as billionaire investor Stanley Druckenmiller highlighted the company as a long-term healthcare pick focused on home and outpatient infusion therapy. Together, these views underscore a tension between the long-term appeal of home-based infusion care and near-term pressures from tougher insurance approvals, therapy...

Limoneira (LMNR) just posted Q2 2026 results with revenue of US$23.9 million and a basic EPS loss of US$1.20, alongside net income excluding extra items of a US$21.5 million loss. Over recent quarters the company has seen revenue move from US$35.1 million in Q2 2025 to US$23.9 million in Q2 2026, with basic EPS shifting from a loss of US$0.20 to a loss of US$1.20. Those trends keep the spotlight firmly on cost control and overall margins. The latest print leaves investors weighing modest...

If you are wondering whether Kinder Morgan's current share price still offers value, or if most of the opportunity is already priced in, this article walks through what the numbers say about the stock. The share price most recently closed at US$31.84, with returns of 1.5% over the past week, a decline of 1.3% over the past month, 14.9% year to date, 20.5% over the last year, 119.4% over three years and 122.6% over five years. Recent attention on Kinder Morgan has centered on its position in...

T. Rowe Price Group (NasdaqGS:TROW), Transamerica, and TIAA are collaborating on a new retirement plan solution. The offering combines target-date strategies from T. Rowe Price with a fixed annuity aimed at providing guaranteed lifetime income. The solution is intended for employer-sponsored retirement plans and focuses on converting retirement savings into dependable income. The partnership targets key retirement challenges such as longevity risk and the transition from saving to spending...

In early June 2026, Corpay’s Cross-Border business announced it had entered into an agreement with Vålerenga Fotball AS to become the club’s Official Foreign Exchange Supplier, providing FX risk management tools and a single-access global payments platform to support its international operations. This agreement highlights how Corpay is extending its cross-border capabilities into new customer verticals such as professional sports organizations, potentially broadening its use cases and client...

Pitney Bowes recently opened a 75,000-square-foot, highly automated Presort Services operating center in Phoenix, equipped with eight high-speed sorters, a connected conveyor system, and 17 dock doors, staffed across three shifts to handle First-Class Mail within its nationwide network. This expansion underscores the company’s push to boost processing capacity and efficiency across its Presort network, even as overall mail volumes face structural pressure. We’ll now examine how this new...

In early June 2026, Teva Pharmaceutical Industries reported new clinical data from three studies showing that AUSTEDO and AUSTEDO XR improved tardive dyskinesia symptoms, daily functioning, and diagnosis rates when presented at Psych Congress Elevate in Las Vegas. The findings, including real-world evidence from the IMPACT-TD Registry and long-term outcomes from the RIM-TD study, suggest that sustained treatment and caregiver education can meaningfully enhance recognition and management of...

Newmark Group (NMRK) has been in focus after a 4.2% share price move, alongside strong May retail sales data and a series of sizeable commercial real estate and digital infrastructure deals. See our latest analysis for Newmark Group. That 4.2% move sits within a mixed pattern, with the 7-day share price return of 7.23% partly offsetting a 30-day share price decline of 9.38%. The 1-year total shareholder return of 28.60% points to stronger longer term momentum. Recent headlines around the...

Matson’s recent earnings report showed a year-on-year revenue decline and a revenue miss versus analyst forecasts, but operating income surpassed expectations thanks to stronger post-Lunar New Year freight demand on its China service. Weaker volumes in Hawaii and Alaska reduced domestic logistics income, suggesting Matson’s earnings profile is increasingly influenced by the performance of its international China-linked operations. We’ll now examine how the stronger-than-expected operating...

Earlier this quarter, AMETEK reported record first-quarter 2026 results, with sales up 11% year over year and adjusted EPS rising 13%, and management raised full-year adjusted EPS guidance while projecting high-single-digit sales growth and double-digit Q2 EPS growth. Beyond the headline records, the stronger outlook signals management’s confidence that demand for AMETEK’s higher-value instrumentation and automation solutions remains resilient across key end markets. We’ll now examine how...

Recently, Materion received an analyst upgrade to a more favorable rating, reflecting increased confidence in its earnings outlook and underlying business performance. This shift in analyst sentiment highlights how rising earnings estimates can influence investor expectations for a company focused on advanced engineered materials. Next, we’ll examine how this more optimistic earnings outlook might reshape Materion’s existing investment narrative and risk-reward profile. Capitalize on the AI...

In early June 2026, Viavi Solutions introduced its first NITRO AI “AI Experts” suite and the ultra-compact µPNT GDO-1000 timing module, embedding task-specific AI guidance and advanced GNSS-disciplined timing directly into its test and measurement platforms for wireless, lab, and mission-critical applications. By fusing AI-driven automation with precision timing hardware across wireless, data center, and defense uses, Viavi is deepening its role inside increasingly complex, software-defined...

In early June 2026, Sabra Health Care REIT drew fresh attention after posting better-than-expected first-quarter results and presenting at Nareit REITweek in New York, where senior leaders outlined the company’s latest updates to investors. This stronger quarter, combined with public support from asset manager Jenny Van Leeuwen Harrington on CNBC, has refocused investors on Sabra’s fundamentals following a recent losing streak. Building on this combination of a robust quarterly report and...

Harrow recently re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% in the US for vernal keratoconjunctivitis, backed by a commercial push around physician education, patient access, and affordability for this serious allergic eye disease that primarily affects children. The move reintroduces what has been described as a steroid-sparing therapy option into a market where many pediatric VKC patients remain inadequately controlled and long-term steroid use carries meaningful safety...

Recent performance snapshot Albemarle (ALB) has drawn fresh attention after a period of weak share performance, with the stock down about 3.6% on the day, 12.5% over the past week, and 30% over the past month. See our latest analysis for Albemarle. These short term share price losses sit alongside a year to date share price return of 2.3% and a very large 1 year total shareholder return, suggesting recent momentum has faded after a strong rebound. If Albemarle's swings have you thinking about...

CNO Financial Group recently hit a new 52-week high after reporting a series of earnings results that exceeded consensus estimates, including April’s US$1.29 per-share figure versus expectations of US$0.91. This consistent pattern of earnings outperformance, coupled with positive analyst estimate revisions and favorable value metrics, is drawing increased attention to CNO’s execution and earnings quality. Next, we’ll examine how this sustained earnings outperformance and analyst optimism may...

If you are wondering whether Goosehead Insurance at US$38.62 offers value or just extra risk, the key is to peel back the recent share price moves and see what they imply about the stock. The share price is up 12.4% over the past week, even though it is down 3.8% over the past month, 45.0% year to date, and 64.1% over the past year, which naturally raises questions about what the market is now pricing in. Recent coverage has focused on Goosehead Insurance's position in the US insurance...